# A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

> **NCT03924947** · PHASE4 · COMPLETED · sponsor: **AbbVie** · enrollment: 36 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Pancrelipase
- **DRUG:** Pancrelipase

## Key facts

- **NCT ID:** NCT03924947
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-23
- **Primary completion:** 2022-07-11
- **Final completion:** 2022-07-11
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03924947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03924947, "A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03924947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*